Home|Journals|Articles by Year|Audio Abstracts
 

Original Research

Ann Med Res. 1999; 6(2): 100-106


Are there any differences betzeen ranitidin or famotidin plus dual antibiotic combination in patients with Helicobacter pylori positive nonulcer dyspepsia ?

Dr. Murat ALADAĞ* Dr. Melih KARINCAOĞLU * Dr. Bülent KANTARÇEKEN* Dr. Yüksel SEÇKİN * Dr. İbrahim DOĞAN* Dr. Funda BAHÇECİ** Dr. Bülent YILDIRIM* Dr. Fatih HİLMİOĞLU *

.




Abstract


H2 blockers have been used in gastric and duodenal ulcer and non-ulcer dyspepsia for years. Nowadays these drugs are used for maintenance therapy after Helicobacter pyolori (Hp) eradication. Aim of this study was to evaluate the effcacy and differences of ranitidin and famotidin plus dual antibiotic therapy in Hp positive non-ulcer dyspepsia patients. Hp positive patients with documented non-ulcer dyspepsia were randomised into two groups. First group was given amoxicillin 1gr bid, clarithromycin 500 mg bid for one week plus ranitidin 300 mg one a day for one month and second group was given amoxicillin 1 gr bid, clarithromycine 500 mg bid for one week plus famotidin 40 mg one a day for one month. Endoscopy with a biopsy was performed at enrollement and at 6 weeks. Hp infection was cured % 83,3 of those treated with ranitidin plus dual antibiotics (RAC) and in % 82.6 of those treated with famotidin plus dual antibiotics (FAC). Sypmptoms disappeared in % 87.5 of those treated with ranitidin plus dual antibiotics and in % 86.95 of those treated with famotidin and dual antibiotics. There were not any statistically significant differences between famotidin or ranitidin plus dual antibiotics combinations in patients with Hp positive non-ulcer dyspepsia.

Key words: H2 blockers, amoxicillin, clarithromycin, Helicobacter pylori eradication.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.